Science News
from research organizations

Novel mouse model of demyelinating disorder

Date:
January 20, 2010
Source:
Cold Spring Harbor Laboratory
Summary:
In a new study, researchers describe how mutation of a gene called ZFP191 leads to disordered central nervous system myelination in mice -- reminiscent of what is seen in human multiple sclerosis patients.
Share:
       
FULL STORY

In the February 1st issue of Genes & Development, Dr. Brian Popko (The University of Chicago) and colleagues describe how mutation of a gene called ZFP191 leads to disordered central nervous system (CNS) myelination in mice -- reminiscent of what is seen in human multiple sclerosis (MS) patients.

MS is a chronic autoimmune disorder, in which the body attacks and destroys the myelin sheath that insulates and protects nerve fibers of the central nervous system (the brain, spinal cord and optic nerves). Demyelination disrupts the conduction of electrical impulses along nerve fibers, and results in regional neural deficits. MS symptoms range from tingling and numbness in limbs, to loss of vision and paralysis.

It is estimated that MS affects 400,000 people in the US and approximately 2.5 million worldwide.

Dr. Popko and colleagues identified a gene called ZFP191 as being necessary for the development of oligodendrocyte cells, which -- in their fully mature form -- produce myelin. The researchers found that mice harboring a single mutation in ZFP191 display tremors and seizures, caused by a severe deficiency in CNS myelination.

ZFP191 appears to be the first factor identified to be critical for the myelinating function of oligodendrocytes.

The failure of Zfp191-mutant mouse oligodendrocytes to successfully myelinate their targets is reminiscent of human MS lesions, where re-myelination of damaged tracts fails to occur efficiently even when apparently mature oligodendrocytes are present in the area.

While further research to delineate the precise targets of ZFP191 is needed, this work holds promising clinical value as a potential therapeutic pathway to promote re-myelination, reduce the accumulation of MS lesions and slow disease progression.

The paper will be released online ahead of print at www.genesdev.org.


Story Source:

The above post is reprinted from materials provided by Cold Spring Harbor Laboratory. Note: Materials may be edited for content and length.


Cite This Page:

Cold Spring Harbor Laboratory. "Novel mouse model of demyelinating disorder." ScienceDaily. ScienceDaily, 20 January 2010. <www.sciencedaily.com/releases/2010/01/100114171531.htm>.
Cold Spring Harbor Laboratory. (2010, January 20). Novel mouse model of demyelinating disorder. ScienceDaily. Retrieved July 28, 2015 from www.sciencedaily.com/releases/2010/01/100114171531.htm
Cold Spring Harbor Laboratory. "Novel mouse model of demyelinating disorder." ScienceDaily. www.sciencedaily.com/releases/2010/01/100114171531.htm (accessed July 28, 2015).

Share This Page: